NEUTROPENIC DEATH and SEVERE HYPERSENSITIVITY
See full prescribing information for complete boxed warning.
- TRADE NAME: Jevtana (Sanofi-Aventis)
- INDICATIONS: Hormone-refractory metastatic prostate cancer (in combination with prednisone)
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Microtubule inhibitor
- HALF-LIFE: α-, β-, and γ-half-lives of 4 minutes, 2 hours, and 95 hours, respectively
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antineoplastics, Atazanavir, BCG Vaccine, Carbamazepine, Cardiac glycosides, Clarithromycin, Clozapine, Conivaptan, CYP3A4 inhibitors and inducers, Dasatinib, Deferasirox, Denosumab, Doxorubicin, Echinacea, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Leflunomide, Natalizumab, Nelfinavir, Phenobarbital, Phenytoin, Pimecrolimus, Rifabutin, Rifampin, Ritonavir, Saquinavir, Sipuleucel-T, St John's Wort, Tacrolimus, Telithromycin, Trastuzumab, Vaccines, Vitamin K antagonists, Voriconazole
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Page last updated 04/10/2025
